欧文論文のみを示す. from 2015 move to http://www.tmd.ac.jp/dept/hcs/lmgh/results/index.html

  1. Suzuki S, Kudo H, Koyama T: Assessment of spontaneous platelet aggregation using laser light scattering in healthy subjects: an attempt to standardize. Int J Lab Hematol 2014;36:676-685.
  2. Takedani H, Shima M, Horikoshi Y, Koyama T, Fukutake K, Kuwahara M, Ishiguro N: A 10-year experience of recombinant activated factor VII use in surgical patients with congenital haemophilia with inhibitors or acquired haemophilia in Japan. Haemophilia 2014; in press.
  3. Yoshimori M, Imadome K, Komatsu H, Wang L, Saitoh Y, Yamaoka S, Fukuda T, Kurata M, Koyama T, Shimizu N, Fujiwara S, Miura O, Arai A: CD137 expression is induced by Epstein-Barr virus infection through LMP1 in T or NK cells and mediates survival promoting signals. PLoS One 2014;9(11):e112564.
  4. Furuhata M, Doki N, Hishima T, Okamoto T, Koyama T, Kaito S, Oshikawa G, Kobayashi T, Kakihana K,  Sakamaki H, Ohashi K: Acquired factor X deficiency associated with atypical AL-amyloidosis. Int Med 2014;53:1841-1845.
  5. Ogawa A, Fujimoto K, Hayashi A, Chida S, Sato K, Takai K, Masaki T, Suzuki A, Kamata Y, Takano K, Koyama T, Shichiri M: Physiological fluctuations of human plasma total salusin-β, an endogenous parasympathomimetic/proatherosclerotic peptide. Peptides 2014;59C:83-88.
  6. Wang L, Sato-Otsubo A, Sugita S, Takase H, Mochizuki M, Usui Y, Gotoh H, Koyama T, Akiyama H, Miura O, Ogawa S, Arai A: High-resolution genomic copy number profiling of primary intraocular lymphoma by single nucleotide polymorphism microarrays. Cancer Sci 2014;105:592-599.
  7. Miura T, Ban D, Koyama T, Kudo A, Ochiai T, Irie T, Nakamura N, Tanaka S, Arii S: Severe postoperative hemorrhage due to antibody-mediated coagulation factor deficiencies: report of two cases. Surg Today 2014;44:976-981.
  8. Fujimoto K, Hayashi A, Kamata Y, Ogawa A, Watanabe T, Ichikawa R, Iso Y, Koba S, Kobayashi Y, Koyama T, Shichiri M: Circulating levels of human salusin-β, a potent hemodynamic and atherogenesis regulator. PLoS One 2013;8(10):e76714.
  9. Koyama T, Fujimoto K, Shima M: Acquired von Willebrand syndrome associated with Hashimoto's thyroiditis and subcutaneous mucosa-associated lymphoid tissue lymphoma. Int Med 2013;52:2661-2663.
  10. Isozumi Y, Arai R, Fujimoto K, Koyama T: Activation of coagulation by lenalidomide-based regimens for the treatment of multiple myeloma. PLoS One 2013;8(5):e64369.
  11. Nakaima Y, Watanabe K, Koyama T, Miura O, Fukuda T: CD137 is induced by the CD40 signal on chronic lymphocytic leukemia B cells and transduces the survival signal via NF-κB activation. PLoS One 2013;8(5):e64425.
  12. Watanabe T, Sato K, Itoh F, Noguchi Y, Fujimoto K, Koyama T, Shichiri M: Emerging roles for vasoactive peptides in diagnostic and therapeutic strategies against atherosclerotic cardiovascular diseases. Curr Protein Pept Sci 2013;14:472-480.
  13. Inaba H, Koyama T, Shinozawa K, Amano K, Fukutake K: Identification and characterization of an adenine to guanine transition within intron 10 of the factor VIII gene as a causative mutation in a patient with mild hemophilia A. Haemophilia 2013;19:100-105.
  14. Kageyama Y, Ikeda H, Watanabe N, Nagamine M, Kusumoto Y, Yashiro M, Satoh Y, Shimosawa T, Tomiya T, Inoue Y, Nishikawa T, Ohtomo N, Tanoue Y, Koyama T, Okamoto Y, Takuwa Y, Koike K, Yatomi Y: Antagonism of sphingosine 1-phosphate receptor 2 causes a selective reduction of portal vein pressure in bile duct-ligated rats. Hepatology 2012;56:1427-1438.
  15. Kanamori E, Itoh M, Tojo N, Koyama T, Nara N, Tohda S: Flow cytometric analysis of Notch1 and Jagged1 expression in normal blood cells and leukemia cells. Exp Ther Med 2012;4:397-400.
  16. Hoshi A, Matsumoto A, Chung J, Isozumi Y, Koyama T: Activation of coagulation by a thalidomide-based regimen. Blood Coagul Fibrinolysis 2011;22:532-540.
  17. Arai A, Imadome K, Watanabe Y, Yoshimori M, Koyama T, Kawaguchi T, Nakaseko C, Fujiwara S, Miura O: Clinical features of adult-onset chronic active Epstein-Barr virus infection: a retrospective analysis. Int J Hematol 2011;93:602-609.
  18. Fischer S, Nishio M, Dadkhahi S, Gansler J, Saffarzadeh M, Shibamiya A, Kral N, Baal N, Koyama T, Deindl E, Preissner KT: Expression and localization of vascular ribonucleases in endothelial cells. Thromb Haemost 2011;105:345-355.
  19. Tsubokura M, Yamashita T, Inagaki L, Kobayashi T, Kakihana K, Wakabayashi S, Ohashi K, Ikezoe T,  Asakura H, Koyama T, Tanimoto T, Kami M, Sakamaki H, Akiyama H: Fatal intracranial hemorrhage following administration of recombinant thrombomodulin in a patient after cord blood transplantation. Bone Marrow Transplant 2011;46:1030-1031.
  20. Kimoto S, Sato K, Watanabe T, Suguro T, Koyama T, Shichiri M: Serum levels and urinary excretion of salusin-a in renal insufficiency. Regul Peptides 2010;162:129-132.
  21. Sato K, Fujimoto K, Koyama T, Shichiri M: Release of salusin-b from human monocytes/macrophages. Regul Peptides 2010;162:68-72.
  22. Koyama T: Managing acquired hemophilia viewed by practical cases. Handbook of Hematology Research: Hemorheology, Hemophilia and Blood Coagulation edited by Tondre R and Lebègue C. 2009:311-316. Nova Science Publishers, Inc., NY.
  23. Koyama T, Chung J, Tabuchi N: Activation of extrinsic coagulation system due to the increase in tissue-factor bearing leukocytes during and after cardiac surgery. APJOH 2009;1:67-76.
  24. Sato K, Sato T, Susumu T, Koyama T, Shichiri M: Presence of immunoreactive salusin-b in human plasma and urine. Regul Peptides 2009;158:63-67.
  25. Fischer S, Nishio M, Peters SC, Walberer M, Tschernatsch M, Weidemann S,  Heidenreich R, Couraud P-O, Weksler BB, Romero IA, Gerriets T, Preissner KT. Signaling mechanism of extracellular RNA in endothelial cells. FASEB J 2009;23:2100-2109.
  26. Nakayama C, Shichiri M, Sato K, Hirata Y. Expression of prosalusin in human neuroblastoma cells. Peptides 2009;30:1362-1367.
  27. Shibamiya A, Hersemeyer K, Schmidt-Woell T, Sedding D, Daniel J-M, Bauer S, Koyama T, Preissner KT, Kanse SM: A key role for toll-like receptor-3 (TLR3) in disrupting the hemostasis balance on endothelial cells. Blood 2009;113:714-722.
  28. Nonaka M, Uota S, Saitoh Y, Takahashi M, Sugimoto H, Amet T, Arai A, Miura O, Yamamoto N, Yamaoka S: Role for protein geranylgeranylation in adult T-cell leukemia cell survival. Exp Cell Res 2009;315:141-150.

  29. Nemoto N, Suzuki S, Kikuchi H, Okabe H, Sassa S, Sakamoto S: Ethyl-eicosapentaenoic acid reduces liver lipids and lowers plasma levels of lipids in mice fed a high-fat diet. In Vivo 2009;23:685-689.
  30. Sato K, Koyama T, Shichiri M. Biosynthesis and secretion of salusin-a from human cells. Peptides 2008;29:2203-2207.

  31. Chung J, Tabuchi N, Koyama T: The increase in tissue-factor bearing leukocytes after off-pump coronary artery bypass surgery. Thromb Haemost 2008;100:952-954.
  32. Nishio M, Koyama T, Nakahara M, Egawa N, Hirosawa S: Proteasome degradation of protein C and plasmin inhibitor mutants. Thromb Haemost 2008;100:405-412.
  33. Kurosu T, Tsuji K, Ohki M, Miki T, Yamamoto M, Kakihana K, Koyama T, Taniguchi S, Miura O: A variant-type MLL/SEPT9 fusion transcript in adult de novo acute monocytic leukemia (M5b) with t(11;17)(q23;q25). Int J Hematol 2008;88:192-196.

  34. Watanabe T, Nishio K, Kanome T, Matsuyama T, Koba S, Sakai T, Sato K, Hongo S, Nose K, Ota H, Kobayashi Y, Katagiri T, Shichiri M, Miyazaki A. Impact of salusin-a and -b on human macrophage foam cell formation and coronary atherosclerosis. Circulation 2008;117:638-648.
  35. Watanabe T, Suguro T, Sato K, Koyama T, Nagashima M, Kodate S, Hirano T, Adachi M, Shichiri M, Miyazaki A: Serum salusin-a levels are decreased and correlated negatively with carotid atherosclerosis in hypertensive patients. Hypertens Res 2008;31:465-470.

  36. Chung J, Suzuki H, Tabuchi N, Sato K, Shibamiya A, Koyama T: Identification of tissue factor and platelet-derived particles on leukocytes during cardiopulmonary bypass by flow cytometry and immunoelectron microscopy. Thromb Haemost 2007;98:368-374.
  37. Teng Y, Takahashi Y, Yamada M, Kurosu T, Koyama T, Miura O, Miki T: IRF4 negatively regulates proliferation of germinal center B cell-derived Burkitt's lymphoma cell lines and induces differentiation toward plasma cells. Eur J Cell Biol 2007;86:581-589.
  38. Suzuki N, Shichiri M, Akashi T, Sato K, Sakurada M, Hirono Y, Yoshimoto T, Koyama T, Hirata Y: Systemic distribution of salusin expression in the rat. Hypertens Res 2007;30:1255-1262.
  39. Kogoshi H, Sato T, Koyama T, Nara N, Tohda S: γ-Secreatase inhibitors suppress the growth of leukemia and lymphoma cells. Oncol Rep 2007;18:77-80.
  40. Chung J, Koyama T, Ohsawa M, Shibamiya A, Hoshi A, Hirosawa S: 1,25(OH)2D3 blocks TNF-induced monocytic tissue factor expression by inhibition of transcription factors AP-1 and NF-kB. Lab Invest 2007;87:540-547.

  41. Kannemeier C, Shibamiya A, Nakazawa F, Trusheim H, Ruppert C, Markart P, Song Y, Tzima E, Kennerknecht E, Niepmann M, von Bruehl M-L, Sedding D, Massberg S, Günther A, Engelmann B, Preissner KT: Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. PNAS 2007;104:6388-93.

  42. Shibamiya A, Muhl L, Tannert-Otto S, Preissner KT, Kanse SM: Nucleic acids potentiate factor VII activating protease (FSAP) - mediated cleavage of platelet derived growth factor-BB and inhibition of vascular smooth muscle cell proliferation. Biochem J 2007;404:45-50.
  43. Kurosu T, Tsuji K, Kida A, Koyama T, Yamamoto M, Miura O: Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-δ. Oncogene 2007;26:2975-2987.
  44. Sato K, Koyama T, Tateno T, Hirata Y, Shichiri M: Presence of immunoreactive salusin-a in human serum and urine. Peptides 2006;27:2561-66.
  45. Koyama T, Nagao T, Tsunozaki H, Arai M, Miura O: Successful management of massive intraperitoneal bleeding in a hemophilia A patient with inhibitor by surgical debridement of the incomplete hematoma and administration of recombinant factor VIII and activated factor VII. Pathophysiol Haemost Thromb 2006;35:405-407.
  46. Shimoyama T, Tabuchi N, Chung J, Koyama T, Sunamori M: Matrix metalloproteinase inhibitor (ONO-4817) attenuates ischemia-reperfusion injury in rat lung. Med Sci Monit 2006;12: BR51-56.

  47. Fu L, Kogoshi H, Nara N, Tohda S: NOTCH1 mutations are rare in acute myeloid leukemia. Leuk Lymphoma 2006;47:2400-3.
  48. Tohda S, Sato T, Kogoshi H, Fu L, Sakano S, Nara N. Establishment of a novel B-cell lymphoma cell line with suppressed growth by gamma-secretase inhibitors. Leuk Res 2006;30:1385-90.
  49. Jin A, Kurosu T, Tsuji K, Mizuchi D, Arai A, Fujita H, Hattori M, Minato N, Miura O: BCR/ABL and IL-3 activate Rap1 to stimulate the B-Raf/MEK/Erk and Akt signaling pathways and to regulate proliferation, apoptosis, and adhesion. Oncogene 2006;25:4332-4340.
  50. Nakazawa F, Kannemeier C, Shibamiya A, Song Y, Tzima E, Schubert U, Koyama T, Niepmann M, Trusheim H, Engelmann B, Preissner KT: Extracellular RNA is a natural cofactor for the (auto-) activation of Factor VII-activating protease (FSAP). Biochem J 2005;385:831-838.
  51. Kogoshi H, Tohda S, Fu L, Koyama T, Nara N: Effect of Notch ligands on in vitro sensitivity to chemo-therapeutic drugs in leukemia and lymphoma cells. Oncol Rep 2005;14:723-6.
  52. Kurosu T, Takahashi Y, Fukuda T, Koyama T, Miki T, Miura O: p38 MAP kinase plays a role in G2 checkpoint activation and inhibits apoptosis of human B cell lymphoma cells treated with etoposide. Apoptosis 2005;10:1111-20.
  53. Tohda S, Kogoshi H, Murakami N, Sakano S, Nara N: Diverse effects of the Notch ligands Jagged1 and Delta1 on the growth and differentiation of primary acute myeloblastic leukemia cells. Exp Hematol 2005;33:558-63.

  54. Yoshizaki T, Tabuchi N, van Oeveren W, Shibamiya A, Koyama T, Sunamori M: PMEA polymer-coated PVC tubing maintains anti-thrombogenic properties during in vitro whole blood circulation. Int J Artif Organs 2005;28:834-40.
  55. Yamamoto K, Itoh T, Abe D, Shimizu M, Kanda T, Koyama T, Nishikawa M, Tamai T, Ooizumi H, Yamada S: Identification of putative metabolites of docosahexaenoic acid as potent PPARγ agonists and antidiabetic agents. Bioorg Med Chem Lett 2005;15:517-22.
  56. Murata-Ohsawa M, Tohda S, Kogoshi H, Sakano S, Nara N: The Notch ligand, Delta-1, alters retinoic acid (RA)-induced neutrophilic differentiation into monocytic and reduces RA-induced apoptosis in NB4 cells. Leuk Res 2005;29:197-203.
  57. Murata-Ohsawa M, Tohda S, Kogoshi H, Nara N: The Notch ligand, Delta-1, reduces TNF-b-induced growth suppression and apoptosis by decreasing activation of caspases in U937 cells. Int J Mol Med 2004;14:861-866.
  58. Nakahara M, Koyama T, Nakazawa F, Nishio M, Shibamiya A, Hirosawa S: Gradually glycosylated protein C mutants (Arg178Gln and Cys331Arg) are degraded by proteasome after mannose trimming. Thromb Haemost 2004;92:1284-1290.
  59. Shibamiya A, Tabuchi N, Sunamori M, Chung J, Koyama T: Formation of tissue factor-bearing leukocytes during and after cardiopulmonary bypass. Thromb Haemost 2004;92:124-131.
  60. Tabuchi N, Shichiri M, Shibamiya A, Koyama T, Nakazawa F, Chung J, Hirosawa S, Sunamori M: Non-viral in vivo thrombomodulin gene transfer prevents early loss of thromboresistance of grafted veins. Eur J Cardio-Thorac 2004;26:995-1001.
  61. Ohsawa M, Koyama T, Nara N, Hirosawa S: Induction of tissue factor expression in human monocytic cells by protease inhibitors through activating activator protein-1 (AP-1) with phosphorylation of Jun-N-terminal kinase and p38. Thromb Res 2003;112:313-320.
  62. Tabuchi N, Shibamiya A, Koyama T, Fukuda T, van Oeveren W, Sunamori M: Activated leukocytes adsorbed on the surface of an extracorporeal circuit. Artificial Organs 2003;27:591-594.
  63. Nakazawa F, Koyama T, Shibamiya A, Hirosawa S: Characterization of thrombomodulin gene mutations of the 5'-regulatory region. Atherosclerosis 2002;164:385-387.
  64. Yoshinaga H, Nakahara M, Koyama T, Shibamiya A, Nakazawa F, Miles LA, Hirosawa S, Aoki N: A single thymine nucleotide deletion responsible for congenital deficiency of plasmin inhibitor. Thromb Haemost 2002;88:144-148.
  65. Suzuki K, Koyama T, Kobayashi S, Kobayashi K, Inagaki K, Abe Y, Kuriyama K, Shiba K: Novel method for detection of ex vivo tumor necrosis factor a production by monocytes.J Clin Lab Anal 2002;16:273-278.
  66. Yamamoto K Shibata F, Miyasaka N, Miura O: The human perforin gene is a direct target of stat 4 activated by IL-12 in NK cells. Biochem Biophys Res Comm 2002;297:1245-1252.
  67. Yamamoto K Shibata F, Yamaguchi M, Miura O: Fusion of MLL and MSF in adult de novo acute myelomonocytic leukemia (M4) with t(11;17)(q23;q25). Int J Hematol 2002;75:503-507.
  68. Koyama T, Ohsawa M, Nakazawa F, Shibamiya A: Anticoagulant effects of synthetic retinoids and activated vitamin D3(1,25(OH)2D3) analogs. Modern Trends in Skin Pharmacology: Molecular and Clinical Aspects, 189-215, edited by Tsambaos D & Merk H. Parissianos Medical Publishers, Athens, Greece, 2002.
  69. Madoiwa S, Nakamura Y, Mimuro J, Furusawa S, Koyama T, Sugo T, Matsuda M, Sakata Y: Autoantibody against prothrombin aberrantly alters the proenzyme to facilitate formation of a complex with its physiological inhibitor antithrombin III without thrombin conversion. Blood 2001;97:3783-3789.
  70. Tabuchi N, Koyama T, Shibamiya A, Sunamori M: Remaining procoagulant property of wound blood washed by a cell-saving device. Ann Thorac Surg 2001;71:1749.
  71. Matsuda K, Hiratsuka N, Koyama T, Kurihara Y, Hotta O, Itoh Y, Shiba K: S ensitive method for detection and semiquantification of Bence Jones protein by cellulose acetate membrane electrophoresis using colloidal silver staining. Clin Chem 2001;47:763-766.
  72. Ohsawa M, Koyama T, Yamamoto K, Hirosawa S, Kamei S, Kamiyama R: 1 a ,25-dihydroxyvitamin D3 and its potent synthetic analogs downregulate tissue factor and upregulate thrombomodulin expression in monocytic cells, counteracting the effects of tumor necrosis factor and oxidized LDL. Circulation 2000;102:2867-2872.
  73. Kikuchi M, Miki T, Kumagai T, Fukuda T, Kamiyama R, Miyasaka N, Hirosawa S: Identification of negative regulatory regions within the first exon and intron of the BCL6 gene. Oncogene 2000;19:4941-4945.
  74. Ohsawa M, Koyama T, Shibakura M, Kamei S, Hirosawa S: Arsenic trioxide (As2O3) gradually downregulates tissue factor expression without affecting thrombomodulin expression in acute promyelocytic leukemia cells. Leukemia 2000;14:941-943.
  75. Yamamoto K, Shibata F, Miura O, Kamiyama R, Hirosawa S, Miyasaka N: Physical interaction between interleukin-12 receptor b 2 subunit and Jak2  tyrosine kinase: Jak2 associates with cytoplasmic membrane-proximal region of interleukin-12 receptor b 2 via amino-terminus. Biochem Biophys Res Comm 1999;257:400-404.
  76. Nakazawa F, Koyama T, Saito T, Shibakura M, Yoshinaga H, Chung DH, Kamiyama R, Hirosawa S: Thrombomodulin with the Asp468Tyr mutation is expressed on the cell surface with normal cofactor activity for protein C activation. Br J Haematol 1999;106:416-420.
  77. Kumagai T, Miki T, Kikuchi M, Fukuda T, Miyasaka N, Kamiyama R, Hirosawa S: The proto-oncogene Bcl6 inhibits apoptotic cell death in differentiation-induced mouse myogenic cells. Oncogene 1999;18:467-475.
  78. Shibakura M, Koyama T, Ohsawa M, Kamiyama R, Hirosawa S: A retinoic acid receptor- a (RAR a ) selective agonist modulates procoagulant activity of acute promyelocytic cells and induces their differentiation into neutrophils. Blood 1998;91:724-725.
  79. Chin H, Arai A, Wakao H, Kamiyama R, Miyasaka N, Miura O: Lyn physically associates with the erythropoietin receptor and may play a role in activation of the Stat5 pathway. Blood 1998;91:3734-3745.
  80. Koyama T, Shibakura M, Ohsawa M, Kamiyama R, Hirosawa S: Anticoagulant effects of 1 a ,25-dihydroxyvitamin D3on human myelogenous leukemia cells and monocytes. Blood 1998;92:160-167.
  81. Sakasita C, Saito T, Kurosu T, Yoshinaga H, Kumagai T, Yamamoto K, Miki T, Koyama T, Miura O, Nemoto T, Asakawa H, Hirosawa S: Two M-components in a single cell lineage in a patient with a dual isotype secretory B-cell tumor. Br J Haematol 1998;102:791-794.
  82. Koyama T, Hirosawa S: Anticoagulant effects of synthetic retinoids and activated vitamin D3. Semin Thromb Hemost 1998;24:217-226.
  83. Koyama T, Shibakura M: Anticoagulant effects of synthetic retinoids. Leuk Lymphoma 1998;31:71-80.
  84. Koyama T, Aoki N: a 2 -Makroglobulin und Protease Nexin 1: Struktur und Funktion Hamostaselogie, 413-415, edited by Müller-Berghaus G & Pötzsch B, Springer-Verlag, Heidelberg, Germany, 1998
  85. Chin H, Wakao H, Miyajima A, Kamiyama R, Miyasaka N, Miura O: Erythropoietin induces tyrosine phosphorylation of the interleukin-3 receptor b subunit ( b IL3) and recruitment of stat5 to possible stat5-docking sites in bIL3. Blood 1997;89:4327-4336.
  86. Chin H, Saito T, Arai A, Yamamoto K, Kamiyama R, Miyasaka N, Miura O: Erythropoietin and IL-3 induce tyrosine phosphorylation of CrkL and its association with Shc, SHP-2, and Cbl in hematopoietic cells. Biochem Biophys Res Comm 1997;239:412-417.
  87. Shibakura M, Koyama T, Saito T, Shudo K, Miyasaka N, Kamiyama R, Hirosawa S: Anticoagulant effects of synthetic retinoids mediated via different receptors on human leukemia and umbilical vein endothelial cells. Blood 1997;90:1545-1551.
  88. Koyama T, Aoki N: Plasma tissue factor reflects endothelial cell injury rather than upregulation of tissue factor expression. Thromb Haemost 1997;78:972.
  89. Qi H, Koyama T, Nishida K, Miyasaka N, Hirosawa S: Urinary procoagulant activity and tissue factor levels in patients with diabetes mellitus. Haemostasis 1997;27:57-64.
  90. Saito T, Koyama T, Nagata K, Kamiyama R, Hirosawa S: Anticoagulant effects of retinoic acids on leukemia cells. Blood 1996;87:657-665.
  91. Yoshinaga H, Ohashi K, Yamamoto K, Miki T, Miura O, Saito T, Koyama T, Kanazawa A, Nemoto T, Miyasaka N, Kamiyama R, Hirosawa S: Clonal identification of Burkitt's lymphoma arising from lymphocyte-predominant Hodgkin's disease. Br J Haematol 1996;95:380-382.
  92. Koyama T, Aoki N: Plasminogen alteration. Hypercoagulable States; Fundamental Aspects, Acquired Disorders and Congenital Thrombophilia, 389-394, edited by Seghatchian MJ, Samama MM & Hecker SP, CRC-Press, Boca Raton, Florida, 1996.
  93. Koyama T, Saito T, Kusano T, Hirosawa S: Factor V inhibitor associated with Sjögren's syndrome. Br J Haematol 1995;89:893-896.
  94. Koyama T, Koike Y, Toyota S, Miyagi F, Suzuki N, Aoki N: Different NH2-terminal form with 12 additional residues of a2-plasmin inhibitor from human plasma and culture media of HepG2 cells. Biochem Biophys Res Commun 1994;200:417-422.
  95. Koyama T, Nishida K, Sawada M, Ohdama S, Murakami N, Hirosawa S, Kuriyama R, Matsuzawa K, Hasegawa R, Aoki N: Determination of plasma tissue factor antigen and its clinical significance. Br J Haematol 1994;87:343-347.
  96. Koyama T, Hirosawa S, Kawamata N, Tohda S, Aoki N: All-trans retinoic acid (ATRA) upregulates thrombomodulin and downregulates tissue factor expression in acute promyelocytic leukemia cells: Distinct expression of thrombomodulin and tissue factor in human leukemic cells. Blood 1994;84:3001-3009.
  97. Koyama T, Koike Y, Sugahara Y, Aoki N: Purification of human a 2-plasmin inhibitor by a one-step immuno-affinity chromatography procedure. Thromb Res 1992;66:451-454.

  98. Koyama T, Parkinson JF, Aoki N, Bang NU, Muller-Berghaus G, Preissner KT: Relationship between post-translational glycosylation and anticoagulant function of secretable, recombinant mutants of human thrombomodulin. Br J Haematol 1991;78:515-522.
  99. Koyama T, Parkinson JF, Sie P, Bang NU, Muller-Berghaus G, Preissner KT: Different glycoforms of human thrombomodulin: Their glycosaminoglycan-dependent modulatory effects of thrombin inactivation by heparin cofactor II and antithrombin III. Eur J Biochem 1991;198:563-570.
  100. Preissner KT, Koyama T, Muller D, Tschopp J, Muller-Berghaus G: Domain structure of the endothelial cell receptor thrombomodulin as deduced from modulation of its anticoagulant functions: Evidence for a glycosaminoglycan-dependent secondary thrombin-binding site for thrombin. J Biol Chem 1990;265:4915-4922.

  1. 奈良信雄,小山高敏,東克己,三村邦裕 編:最新臨床検査学講座 血液検査学.医歯薬出版,東京.2015
  2. 小山高敏:アンダーソン血液学アトラス(訳)Anderson’s Atlas of Hematology. 2nd edition.メディカル・サイエンス・インターナショナル,東京,2014.
  3. 小山高敏:出血傾向.緊急度・重症度からみた疾患別看護過程+病態関連図.改訂第2版.2014:273-278. 井上智子,稲瀬直彦 編.医学書院,東京.
  4. 小山高敏:血球の生成と崩壊16-25,止血・凝固異常の治療と検査223-228,凝固・線溶因子の異常362-368,及び編集.スタンダード検査血液学第3版,日本検査血液学会 編,医歯薬出版,東京.
  5. 小山高敏:凝固・線溶阻止物質.血液検査学実習書.改訂版.2014:121-141. 三村邦裕 編.医歯薬出版,東京.
  6. 小山高敏: Medical Technology別冊 ガイドライン対応 臨床検査技師国家試験 ファーストトレーニング 臨床検査医学総論39-61医歯薬出版,東京
  7. 小山高敏:出血・凝固検査.わかる!検査値とケアのポイント.第2版.大久保昭行,井上智子 編.印刷中,医学書院,東京.

  8. 小山高敏:臨床検査技師国家試験問題集2015年版 2. 臨床病態学53-93,6. 臨床血液学273-316.医歯薬出版,東京.
  9. 小山高敏:第60回臨床検査技師国家試験問題・解答・解説(血液).Medical Technology 2014;42(6):617-655. 医歯薬出版,東京.
  10. 小山高敏:造血器疾患:最新の治療戦略.後天性凝固因子インヒビター.臨床血液;2014;55(1):67-74.
  11. 小山高敏:播種性血管内凝固(DIC).医師・薬剤師のための医薬品副作用ハンドブック.2013:366-369. 寺本民生 監修.日本臨床社,大阪.
  12. 小山高敏:臨床病態学.臨床検査技師 グリーン・ノート第2版.2013:2-25. 臨床編.芝紀代子 編.メジカルビュー社,東京.
  13. 小山高敏:臨床検査技師国家試験問題集2014年版 2. 臨床病態学51-85,6. 臨床血液学263-308.医歯薬出版,東京.
  14. 小山高敏:第59回臨床検査技師国家試験問題・解答・解説(血液).Medical Technology 2013;41(6):673-712. 医歯薬出版,東京.
  15. 小山高敏:第1章 総論 2013:2-8. 第7章 血液・造血器疾患 2013:95-109. 新臨床検査技術学.臨床医学総論.小山高敏,戸塚実 編.医学書院,東京.
  16. 小山高敏:臨床病態学.臨床検査技師 イエロー・ノート第2版 2013:1-31. 臨床編.芝紀代子 編.メジカルビュー社,東京.
  17. 小山高敏:経口抗凝固薬の作用と適応症.特集:新たな抗凝固薬の展開(編集も担当).Medical Technology 2012;40(11):1185-1189. 医歯薬出版,東京.
  18. 小山高敏:播種性血管内凝固症候群(DIC).疾患別看護過程第2版.2012:775-780. 井上智子,佐藤千史 編.医学書院,東京.
  19. 小山高敏:血液細胞の基礎知識.1. 赤血球の産生と機能.2. 白血球の産生と機能.3. 血小板の産生と機能.顕微鏡検査ハンドブック-臨床に役立つ形態学.186-194,医学書院,東京.
  20. 小山高敏:播種性血管内凝固.日本臨床2012年増刊.医薬品副作用学―薬剤の安全使用アップデート―第2版2012:70 Suppl 6;472-476.日本臨床社,大阪.
  21. 小山高敏:臨床検査技師国家試験問題集2013年版 2. 臨床病態学51-86,6. 臨床血液学261-306.医歯薬出版,東京.

  22. 小山高敏:第58回臨床検査技師国家試験問題・解答・解説(血液).Medical Technology 2012;40(6):665-703. 医歯薬出版,東京.
  23. 小山高敏:播種性血管内凝固症候群(DIC).病気と薬 パーフェクトBOOK 2012.薬局 増刊号 2012; 63(4):693-697. 南山堂,東京.
  24. 影山祐子,横田浩充,常名政弘,佐藤優実子,高井大哉,小山高敏,矢冨裕:AMLにおけるBAALC遺伝子発現定量法の構築とその有用性に関する検討.日本検査血液学会雑誌2012;13(1):17-23.
  25. 小山高敏:出血傾向.2011:272-278. 緊急度・重症度からみた症状別看護過程と病態関連図.井上智子,佐藤千史 編.医学書院,東京.
  26. 小山高敏:臨床検査技師国家試験問題集2012年版 2. 臨床病態学55-85,6. 臨床血液学259-302.医歯薬出版,東京.

  27. 小山高敏:第57回臨床検査技師国家試験問題・解答・解説(血液).Medical Technology 2011;39(6):597-635. 医歯薬出版,東京.
  28. 小山高敏:医心伝身第255回.血栓を抑える抗凝固薬約50年ぶりの新薬承認.週刊ポスト2011:43(29):92.
  29. 小山高敏:播種性血管内凝固症候群(DIC).病気と薬 パーフェクトBOOK 2011.薬局 増刊号 2011;62(4):796-801. 南山堂,東京.
  30. 佐藤健吾,小山高敏,七里眞義:サリューシン-bの物理化学的特性の検討とradioimmunoassay系の確立.臨床病理2011;59(2):121-127.
  31. 小山高敏:人体の構造と機能からみた病態生理ビジュアルマップ3.播種性血管内凝固(DIC).2010:111-117. 佐藤千史,井上智子 編.医学書院,東京.
  32. 小山高敏:国試の常識50.臨床検査医学総論.Medical Technology 2010;38(12):1246-1247.

  33. 小山高敏:播種性血管内凝固.医薬品副作用ハンドブック第2版.2010:381-385. 高橋隆一 編,日本臨床社,大阪.
  34. 小山高敏:播種性血管内凝固症候群(DIC).病気と薬 パーフェクトBOOK 2010.薬局 増刊号 2010;61(4):745-747.
  35. 小山高敏:臨床検査技師国家試験問題集2011年版 2. 臨床病態学57-90,6. 臨床血液学265-309.医歯薬出版,東京,2010.
  36. 小山高敏:第56回臨床検査技師国家試験問題・解答・解説(血液).Medical Technology 2010;38(6):601-640. 医歯薬出版,東京,2010.
  37. 小山高敏:DIC診療の最近の進歩.8. 治療法.臨床血液 2010;51(1):52-56.
  38. 小山高敏:血液凝固活性化の病態とその制御の解析.臨床病理2010;58(1):45-57.
  39. 小山高敏:ワーファリン治療とINR値.Medical Technology 2010;38(3):291-295.
  40. 奈良信雄,小山高敏,東克己,三村邦裕 編:臨床検査学講座 血液検査学 第3版.医歯薬出版,東京,2010.
  41. 小山高敏:血友病(von Willebrand病を含む).今日の治療指針 2009年版,519-522, 医学書院,東京,2009.
  42. 小山高敏:播種性血管内凝固症候群(DIC).病気と薬 パーフェクトBOOK 2009 薬局 増刊号 60(4):652-654, 2009.
  43. 小山高敏:凝固・線溶阻止物質.血液検査学実習書.2009:119-140. 三村邦裕 編.医歯薬出版,東京,2009.
  44. 小山高敏:血液・造血器疾患.臨床検査学講座 臨床病態学.2009:154-173. 松浦雅人 編.医歯薬出版,東京,2009.
  45. 西尾美和子:Journal club; 血管内皮細胞からのVWFの分泌はPhospholipase D1によって特異的に制御されている.血栓止血誌2009;20(3): 367.
  46. 西尾美和子,小山高敏,広沢信作:変異プロテインCと変異プラスミンインヒビターの細胞内分解:先天性タンパク質欠乏症の分子病態.臨床病理2009;57(8):737-745.
  47. 小山高敏:臨床検査技師国家試験問題集2010年版 5. 臨床病態学201-232,8. 臨床血液学335-379.医歯薬出版,東京.2009.
  48. 小山高敏:第55回臨床検査技師国家試験問題・解答・解説(血液).Medical Technology 2009;37(6):625-664. 医歯薬出版,東京.2009.

  49. 小山高敏:血液細胞の基礎知識.1. 赤血球の産生と機能.2. 白血球の産生と機能.3. 血小板の産生と機能.検査と技術 2009年増刊号 顕微鏡検査のコツ-臨床に役立つ形態学.検査と技術 2009;37(10):1056-1064.

  50. 小山高敏:出血傾向.内科確定診断完全マスター 27-33. 斎藤宣彦 監修,Medical View社,東京,2009.

  51. 小山高敏:血液凝固関連項目.医学書院  医学大辞典 第2版,伊藤正男,井村裕夫,高久史麿 編,医学書院,東京,2009.
  52. 小山高敏:末梢血検査異常-何を考え,どう対応するか.23. 出血傾向患者へのアプローチ.medicina 2008; 45(13):2218-2224.
  53. 小山高敏:播種性血管内凝固症候群(DIC).疾患別看護過程.780-785, 井上智子,佐藤千史 編.医学書院,東京,2008.

  54. 金森きよ子,横溝佳代,長雄一郎,新庄貴夫,長裕子,小山高敏,佐藤健次,西牧淳一,芝紀代子:健康増進機器による“エアーマッサージ”が血清成分に及ぼす影響.臨床病理56(6):459-464, 2008.

  55. 小山高敏:臨床検査医学総論.臨床検査臨地実習マニュアル第3版 2−7, 医歯薬出版,東京,2008.
  56. 小山高敏:播種性血管内凝固.医薬品副作用ハンドブック.324-327,高橋隆一 編,日本臨床社,大阪,2008.

  57. 小山高敏:血液の流れやすさは何で決まる? 身近な"?"に答えます.Newton ムック:54-59, 2008.
  58. 小山高敏:播種性血管内凝固症候群(DIC).病気と薬 パーフェクトBOOK 2008 薬局 増刊号 59(4):667-669, 2008.
  59. 小山高敏:血球の生成と崩壊22-32,凝固・線溶因子の異常269-274,及び編集.スタンダード検査血液学第2版,日本検査血液学会 編,医歯薬出版,東京,2008.
  60. 小山高敏:臨床検査技師国家試験問題集2009年版 5. 臨床病態学199-232,8. 臨床血液学337-379.医歯薬出版,東京,2008.

  61. 小山高敏:第54回臨床検査技師国家試験問題・解答・解説(血液).Medical Technology 2008;36(6):631-670. 医歯薬出版,東京,2008.
  62. 小山高敏:播種性血管内凝固症候群(DIC).今日の治療指針 2007年版,493-495, 医学書院,東京,2007.

  63. 小山高敏:止血系(血液凝固・線溶・血小板)検査のEBM.出血性疾患と血栓性疾患の臨床検査概論.Medical Technology 35(2):128-131, 2007,小山高敏 編.医歯薬出版,東京,2007.

  64. 小山高敏:血液の流れやすさは何で決まる?Newton 27(6):90-95, 2007.

  65. 仁多美奈子,新井文子,山本晃,坂下千瑞子,福田哲也,三木徹,小山高敏,村上直巳,三浦修:血球貪食症候群を伴った急性前骨髄球性白血病.臨床血液48(4):310-314, 2007.

  66. 小山高敏:von Willebrand病.血液凝固異常,播種性血管内凝固,血栓性疾患.図説 血液学,押見和夫 編.438-459,中外医学社,東京,2007.
  67. 小山高敏:日本臨床2007年増刊.医薬品副作用学―薬剤の安全使用Update―播種性血管内凝固,493-496, 日本臨床社,大阪,2007.

  68. 小山高敏:第53回臨床検査技師国家試験問題・解答・解説(血液).Medical Technology 35(6):613-652, 医歯薬出版,東京,2007.

  69. 小山高敏:臨床検査技師国家試験問題集2008年版 臨床血液学、臨床病態学.医歯薬出版,東京,2007.
  70. 小山高敏:獲得性凝固因子インヒビターに対する治療法は?EBM 血液疾患の治療2008-2009,532-538押味和夫,別所正美,岡本真一郎,加藤淳 編,中外医学社,東京,2007.
  71. 小山高敏:臨床病態学.臨床検査技師 グリーン・ノート 臨床編.芝紀代子 編.メジカルビュー社,東京,2007.
  72. 小山高敏:臨床病態学.臨床検査技師 イエロー・ノート 臨床編. 芝紀代子 編.1-31,メジカルビュー社,東京,2007.
  73. 小山高敏:発刊にあたって.Medical Technology 増刊号 血栓・塞栓症の病態・検査・治療.Medical Technology 35(13):1321, 2007, 小山高敏 編.医歯薬出版,東京.

  74. 小山高敏:止血機構と血栓症の病態.Medical Technology 増刊号 血栓・塞栓症の病態・検査・治療.Medical Technology 35(13):1326-1337, 2007, 小山高敏 編.医歯薬出版,東京.
  75. 小山高敏:先天性血栓性素因.Medical Technology 増刊号 血栓・塞栓症の病態・検査・治療.Medical Technology 35(13):1456-1461, 2007, 小山高敏 編.医歯薬出版,東京.
  76. 小山高敏:播種性血管内凝固症候群(DIC).薬局 増刊号 病気と薬パーフェクトガイド2008.南山堂,東京,2007.
  77. 小山高敏:血球の生成と崩壊,凝固・線溶因子の異常,及び編集.スタンダード検査血液学第2版,日本検査血液学会 編,医歯薬出版,東京,2007.
  78. 小山高敏:凝固・線溶阻止物質.血液検査学実習書.医歯薬出版,東京,2007.
  79. 小山高敏:播種性血管内凝固,医薬品副作用ハンドブック.日本臨床社,大阪,2007.